Journal of Postgraduate Medicine
 Open access journal indexed with Index Medicus & ISI's SCI  
Users online: 4329  
Home | Subscribe | Feedback | Login 
About Latest Articles Back-Issues Article Submission Resources Sections Etcetera Contact
 
  NAVIGATE Here 
  Search
 
 :: Next article
 :: Previous article 
 :: Table of Contents
  
 RESOURCE Links
 ::  Similar in PUBMED
 ::  Search Pubmed for
 ::  Search in Google Scholar for
 ::Related articles
 ::  Article in PDF (1,956 KB)
 ::  Citation Manager
 ::  Access Statistics
 ::  Reader Comments
 ::  Email Alert *
 ::  Add to My List *
* Registration required (free) 

  IN THIS Article
 ::  Abstract
 ::  Introduction
 ::  Diffusion and Di...
 ::  Perfusion Imaging
 ::  MR Spectroscopy
 ::  Functional MRI
 ::  Imaging of Stroke
 ::  Imaging of Epilepsy
 ::  Imaging in Brain...
 ::  Imaging in Dementia
 ::  Conclusions
 ::  References
 ::  Article Figures

 Article Access Statistics
    Viewed3380    
    Printed106    
    Emailed1    
    PDF Downloaded168    
    Comments [Add]    

Recommend this journal


 


 
SYMPOSIUM
Year : 2010  |  Volume : 56  |  Issue : 2  |  Page : 88-97

Magnetic resonance imaging: Current and emerging applications in the study of the central nervous system


1 Department of Radiology, Kokilaben Dhirubhai Ambani Hospital, Andheri West, Mumbai, Maharashtra, India
2 Department of Radiology, PD Hinduja Hospital and Research Center, Mumbai, Maharashtra, India
3 Department of Radiology, Royal Preston Hospital, Lancashire Teaching Hospitals, NHS Foundation Trust, United Kingdom

Date of Submission12-Feb-2010
Date of Decision28-Mar-2010
Date of Acceptance07-May-2010
Date of Web Publication8-Jul-2010

Correspondence Address:
D A Sanghvi
Department of Radiology, Kokilaben Dhirubhai Ambani Hospital, Andheri West, Mumbai, Maharashtra
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0022-3859.65283

Rights and Permissions


 :: Abstract 

Neuroimaging is presently utilised in clinical practice for initial diagnosis and mapping of disease extent and distribution, noninvasive, preoperative grading of tumours, biopsy planning, surgery and radiation portal planning for tumors, judging response to therapy and finally, prognostication. Newer advances include magnetic resonance (MR) diffusion and diffusion tensor imaging with tractography, perfusion imaging, MR spectroscopy and functional imaging using the blood oxygen level-dependent contrast technique. Neuroimaging plays a pivotal role in various degenerative and neoplastic diseases, improving diagnostic accuracy, affecting patient care, monitoring dynamic changes within the brain during therapy, and establishing them as the arbiter of novel therapy that may one day prove cure of various brain diseases a reality.


Keywords: BOLD, diffusion, perfusion, spectroscopy


How to cite this article:
Sanghvi D A, Patel Z, Patankar T. Magnetic resonance imaging: Current and emerging applications in the study of the central nervous system. J Postgrad Med 2010;56:88-97

How to cite this URL:
Sanghvi D A, Patel Z, Patankar T. Magnetic resonance imaging: Current and emerging applications in the study of the central nervous system. J Postgrad Med [serial online] 2010 [cited 2019 Nov 12];56:88-97. Available from: http://www.jpgmonline.com/text.asp?2010/56/2/88/65283



 :: Introduction Top


Over the past few decades, as novel therapies for patients with neurological and neurosurgical disorders are being developed, we are witnessing a shift in imaging from merely providing anatomical information towards providing information about neurophysiology. Neuroimaging is presently utilised in clinical practice for initial diagnosis and mapping of disease extent and distribution, non invasive, preoperative grading of tumours, biopsy planning, surgery and radiation portal planning for tumors, judging response to therapy and finally, prognostication. Newer advances include magnetic resonance (MR) diffusion and diffusion tensor imaging (DTI) with tractography, perfusion imaging, MR spectroscopy and functional imaging using the blood oxygen level-dependent contrast (BOLD) technique.


 :: Diffusion and Diffusion Tensor Imaging Top


Diffusion-weighted MR imaging is the simplest form of diffusion imaging. [1] It is a pulse sequence sensitised to the random motion of water molecules (which is termed  Brownian motion More Details). Certain pathologies constrain the normal random motion of water molecules in brain tissue and this is referred to as restricted diffusion. Diffusion weighting enables one to distinguish between rapid diffusion of protons (unrestricted diffusion) and slow diffusion of protons (restricted diffusion). Lesions that have restricted diffusion appear hyperintense on diffusion images and hypointense on the accompanying apparent diffusion coefficient (ADC) maps. Using an ADC map it is possible to quantify the diffusion in brain tissues.

A more sophisticated extension of diffusion imaging is diffusion tensor imaging. Diffusion tensor MR imaging is a noninvasive in vivo method for mapping white matter fiber tract trajectories in the human brain. [2] Diffusion tensor imaging is based on the concepts of isotropic and anisotropic diffusion. The movement of water molecules occurs in all three directions.When water molecules diffuse equally in all three directions, this is termed isotropic diffusion. This is typical in the ventricles, but is also true in the grey matter. In the white matter, free water molecules move anisotropically, i.e. water diffusion is not equal in all three directions. This is because in white matter tracts, the myelin sheath surrounding white matter causes water molecules to move more along the long axis of a fiber bundle and less perpendicularly. Maximum diffusivity coincides with the white matter fiber tract orientation.

Information from DTI is presented in two formats which are FA (fractional anisotropy) maps and tractography. FA maps are cross-sectional images that may be in a grey scale format or may be color-coded for directional information. In FA maps structures that have anisotropy i.e. white matter appear bright on grey-scale FA maps and the degree of brightness is proportional to the anisotropy. When a white matter tract is destroyed by say a tumor there is loss of anisotropy and therefore a reduction in the FA values which is manifested on grey-scale FA maps as loss of brightness. FA values can also be quantified numerically. The color FA maps show the direction of white matter tracts. Again the intensity of the color hues is proportional to the extent of anisotropy. In addition to assessment of the diffusion in a single voxel, DTI has been used to map the white matter fiber tracts. These three-dimensional (3D) reconstructions are called tractography. The principle direction of diffusion in a voxel is called the Eigenvector. Tractography is done by connecting a given voxel to the appropriate adjacent voxel in accordance with the direction that the voxels principle eigenvector is oriented .


 :: Perfusion Imaging Top


On imaging the microvascular structure can be studied by high temporal resolution imaging of the passage of the contrast bolus. Following an injection of contrast media the bolus will pass through the vascular bed entering through arterial vessels, passing through the capillaries bed and draining into the venous system. The amount of contrast that passes into the vascular system will depend on the blood flow rate through the vessels and the contrast dose injected. Within any given voxel the amount of intravascular contrast will depend on the proportion of the voxel formed by blood vessels. As contrast passes through the capillary bed it will leak into the extravascular extracellular space (EES). The rate at which this leakage occurs will reflect the difference in contrast concentration between the blood plasma and the EES. For any given concentration ratio the amount of contrast that leaks will also be restricted by the permeability and surface area of the endothelial membrane. Dynamic MR perfusion can be performed using either T2, T2*or T1-weighted images. It can be seen that the behaviour of contrast material within any given voxel will be related to the concentration time course of contrast entering the arterial vessels, the regional blood flow, the local blood volume, and the endothelial permeability, the surface area of the endothelium and the size of the EES. Analysis schemes for dynamic contrast enhanced-MRI are designed to identify biomarkers which represent one of, or combinations of these biological features. Arterial spin labelling is a new perfusion technique that does not require exogenous contrast; instead it exploits the spins of endogenous water protons that perfuse the imaging plane.


 :: MR Spectroscopy Top


MR spectroscopy (MRS) is the only noninvasive technique capable of measuring chemicals within the body. MRS distinguishes various metabolites on the basis of their slightly different chemical shifts or resonance frequencies. Biologically, relevant nuclei that are amenable to MR analysis are those with an odd number of protons and neutrons such as 1 H , 31 P , 13 C , 19 F and 23 Na. Of these, the one we commonly use is hydrogen or proton spectroscopy. The metabolic information received is displayed as a graph. On the X axis are plotted the resonance frequencies which allow us to identify each unique metabolite. These frequencies are plotted in a unit called parts per million (ppm). Using the Y axis, it is possible to quantify the metabolite by either measuring the peak value referred to as the amplitude or the area under the curve, called the integral value. Various ratios are often calculated. Single or multiple voxels of the brain can be interrogated with this technique. Multivoxel spectroscopy is also called chemical shift imaging or CSI. Using CSI it is possible to create visually appealing colour maps or metabolite maps for spatial demonstration of the metabolite peaks and ratios. These colour maps are overlapped or fused with conventional MR techniques to improve anatomical localization.


 :: Functional MRI Top


Functional MRI (F MRI) refers to the demonstration of brain function with neuroanatomic localization on a real-time basis. The vast majority of these studies are performed using BOLD techniquewhich requires the detection of very small signal intensity changes- 0-3% at 1.5 Tesla and up to 6% at 3 Tesla for voxel volumes as small as 3 ΄ 3 ΄ 5 mm. [3] The principle of the BOLD technique of F MRI is that performing a predefined cognitive task leads to regionally increased neuronal activity and localized hemodynamic changes that produce a signal response.


 :: Imaging of Stroke Top


Stroke remains a leading cause of mortality and morbidity in India and the world. The past decade has witnessed dramatic advances in stroke neuroimaging and therapeutics that includes diffusion-perfusion imaging, multidetector computed tomography (CT) angiography and endovascular clot dissolution/retrieval techniques.

Most of these advances have been in the imaging and management of hyperacute ischemic stroke. [4],[5],[6] The primary aim of imaging in hyperacute ischemic stroke is direct management in terms of salvaging the penumbra. Reversal of penumbra is associated with a significant decrease in morbidity and mortality in stroke. Currently, MR perfusion studies in combination with diffusion images are used in the setting of hyperacute ischemic stroke to establish the presence of a penumbra which is an indication for thrombolytic therapy in the first 6 h after the onset of an acute neurologic deficit. Penumbra is the tissue at risk for dying if ischemia continues without recanalization of an intravascular thrombus. The abnormality seen on a diffusion image represents the infarct core where damage is irreversible. The ischemic penumbra is at the area around the infarcted core which may be salvaged by thrombolysis. It is depicted on colour perfusion maps as an area around with the infarct core with elevated mean transit time (MTT), decreased cerebral blood volume (CBV) and decreased cerebral blood flow (CBF). The absence of a significant diffusion- perfusion mismatch implies that the patient will not benefit from thrombolysis. A large diffusion abnormality suggestive of a large infarct associated with a small perfusion abnormality representing a small penumbra should be treated with caution, taking into consideration other factors such as time after onset of symptoms. This is because of a potential increase in the risk of subsequent hemorrhage that is associated with an initial large infarct size. Finally, a small diffusion abnormality representing a small infarct with a large perfusion defect representing a significant penumbra [Figure 1] is an indication for thrombolysis in the absence of hemorrhage. Follow-up imaging of patients with untreated or unsuccessfully treated diffusion-perfusion mismatch exhibit substantial lesion growth on follow-up imaging. On the other hand, those with early complete recanalization do not exhibit lesion progression on follow-up imaging. These observations emphasize the accuracy of diffusion-perfusion imaging in guiding management and in prognostication of patients with acute ischemic stroke.

In the future, selection of patients for thrombolytic therapy may be made effective by performing appropriate imaging studies rather than relying on time of onset as the sole determinant of selection. [7] In recent trials, [8],[9] intravenous desmoteplase injection at 3-9 h after onset was associated with a higher rate of reperfusion and better clinical outcome in patients selected because of a mismatch between the findings of diffusion and perfusion MR images. The symptomatic intracranial hemorrhage rate was also low.

In addition to its critical role in the management of hyperacute stroke, perfusion may also be used to assess stroke risk by measurement of cerebrovascular reserve capacity. [10] The ability of the brain to adapt to sudden onset ischemia and hypoxia by autoregulatory vasodilatation is termed cerebrovascular reserve capacity. In patients with chronic cerebral ischemia due to carotid disease, this autoregulatory mechanism is often exhausted due to long-term lack of blood supply and therefore this subset of patients are at increased risk of significant damage if an acute ischemic event occurs. MR and CT perfusion can demonstrate lack of response in cases of chronic carotid stenosis when performed before and after the administration of an intravenous pharmaceutical that induces vasodilatation such as acetazolamide. Lack of increase in cerebral perfusion after administration of an exogenous vasodilator implies lack of cerebrovascular reserve capacity and increased risk during hemodynamic stress.

Finally, a number of recent studies [11],[12] have highlighted the ability of perfusion MR for evaluating postoperative alteration of cerebral hemodynamics following superficial temporal artery - middle cerebral artery (STA-MCA) anastomosis in patients with Moya Moya disease. These studies have shown that shortening of the time to peak (TTP) in the MCA territory of the hemisphere operated on is a marker of the development of collateral circulation form the external carotid artery to the internal carotid artery.


 :: Imaging of Epilepsy Top


Epilepsy is a common disorder, with a prevalence of 0.4-1% of the population . [13],[14],[15] Apart from being a chronic medical illness, its ill effects affect social and economic life. Imaging plays a role in identifying structural abnormalities which require surgery and in diagnosing a specific syndrome or etiology. MRI is the best for depicting structural abnormality, while nuclear medicine and specialized MR techniques give additional functional information. [16]

CT is now usually performed only in the setting of an emergency and trauma associated with focal neurological deficits. It diagnoses large lesions like tumors, granulomas and vascular malformations. MRI has its distinct advantages due to its multiplanar capability, higher spatial resolution, excellent soft tissue contrast and lack of ionizing radiation. [17] The MRI protocols are tailored depending on the type of seizure. In Temporal lobe epilepsy (TLE), oblique thin coronal T2, FLAIR (fluid attenuated inversion recovery) and T1-weighted gradient volume sequences (SPGR or MP-RAGE) are obtained through the hippocampus. MR findings in histologically proved cases of mesial temporal sclerosis (MTS) are hippocampal atrophy and increased T2 signal [18] [Figure 2]. The 3D SPGR sequence has revolutionized imaging of extratemporal lesions (cortical dysplasia, heterotopias, polymicrogyria etc), its advantage being its excellent spatial resolution and the ability to reformat. Contrast studies are mainly reserved for focal mass lesions, adult onset seizures or a few syndromes. Using a surface coil MRI and high-strength scanners can also aid in locating cortical dysplasia. [19],[20]

In cases of bilateral MTS, one side is affected more than the other in 80% of patients. [21] Quantitative techniques have proved to be useful since they can assess bilaterality and grade the disease. Hippocampal volumetry is one of the MR methods to study the hippocampus quantitatively. [22],[23] The area of the hippocampus is manually measured on each image on the 3D SPGR sequence. A significant difference between the volumes on both sides is a reliable pointer of unilateral hippocampal sclerosis. When the involvement is bilateral the measurements are compared with reference values for the normal population. T2 relaxometry quantifies the T2 hydration. [24] A series of T2W images of different TE are taken through the same slice and the T2 decay is measured. Normally it is less than 110-115 msec. In MTS the T2 time is elevated, and abnormal T2 relaxometry is significantly associated with intractable epilepsy. [25] Proton 1 H spectroscopy as stated earlier maps the various brain metabolites. N-acetyl-aspartate (NAA) is a neuronal marker. Decreased values of NAA/creatinine and NAA/creatinine+choline ratios imply neuronal loss and/or metabolic dysfunction. Decreased ratios have been able to lateralize TLE in 65-90% of patients with bilateral temporal lobe structural abnormalities. [26] In cases of temporal lobe epilepsy (TLE) with normal MR studies, NAA ratios can provide lateralizing evidence in at least 20% of patients. [27] 31 P spectroscopy when done during and after a seizure depicts changes in the pH and high-energy phosphates. [28] Its role in TLE is still controversial.

Functional techniques, including positron emission tomography (PET), single-photon emission computerized tomography (SPECT), and fMRI are useful tools for localizing the epileptogenic zone and mapping functional areas of the brain such as language and motor function. Epilepsy surgery usually involves a resection or disconnection technique which removes or isolates the epileptogenic zone, while sparing functional cortex. [29] fMRI is used for mapping the eloquent cortex before surgery and denote its relationship with the epileptogenic zone. It is particularly useful for children, since there is no radiation exposure, and it is easy to repeat if the test is inconclusive. [30] Presurgical [Figure 3] and postsurgical DTI with 3D tractography is done on some occasions for evaluating the completeness of the surgery and complications in case of new post-surgical deficits. SPECT using blood flow markers such as HMPAO reveals a region of relative hypoperfusion interictally and an ictal focal increase in perfusion. Fluro deoxy glucose (FDG) PET has been more valuable in assessing severe epilepsy in very young children, where it reveals focal hypometabolism amenable to highly successful surgical resection. [31] A comparison of MRI, PET and ictal SPECT, using pathological diagnosis as a standard of reference, showed correct lateralization in 72%, 85% and 73%, respectively. [32]

In spite of the wide range of available MR techniques, there still is a group of MR imaging-negative patients. In these cases novel techniques like diffusion, magnetization transfer imaging (MTI) and T2 mapping and double inversion recovery which identify microstructural abnormalities can be attempted. Decreased anisotropy and increased ADC values are seen in the sclerosed hippocampi in the interictal phase. [33] Whole brain T2 mapping and MTI quantify the T2 and MTR values respectively and corroborate well with the abnormality on conventional images but also help in identifying occult lesions. [34] However, the there is still limited data available and at present their role is mainly for guiding the accurate placement of intracranial electro-encephalogram (EEG) electrodes. [35]


 :: Imaging in Brain Tumors Top


Primary malignant brain tumours are associated with the third highest cancer-related mortality rate with a disproportionate level of disability and morbidity. The current WHO classification, however, falls short of predicting the therapeutic response of each individual tumour within the same histological grade and cannot provide precise guidance of therapy, especially those targeting specific molecular or genetic pathways of tumour genesis . [36],[37] In most cases the radiological diagnosis of brain tumour is obvious but if the nature of the lesion is still in question after comprehensive investigation, further imaging with advanced technique such as diffusion [Figure 4], perfusion or spectroscopy may be warranted to grade tumors, assess cellularity and differentiate brain cancers from tumour-mimicking lesions such as infarcts, abscesses or demyelination. [38],[39],[40]

The analysis of dynamic contrast-enhanced MRI data using pharmacokinetic models which describe the behaviour of contrast within the tissue has enabled the development of specific biological surrogate markers including flow [F], endothelial permeability surface area product [K trans ], blood volume [CBV] and extracellular extravascular tissue volume [Ve].

Dynamic contrast-enhanced MR is being used to assess the vascularity of intracranial lesions in gliomas, [41],[42],[43] tumour-mimicking demyelination [38] and cerebral lymphomas. [44] Increased tumour vascularity is not synonymous with malignancy. There are several intracranial neoplasms; especially those that are extra-axial in location such as meningiomas or choroid plexus papillomas, can be highly vascular but rather benign in biologic behaviour. Differentiation between radiation necrosis and recurrent tumour may be difficult on conventional imaging, however, dynamic contrast-enhanced MR imaging may be able to differentiate as radiation necrosis shows low CBV and K trans . [45],[46],[47],[48],[49],[50] Meningiomas are highly vascular extra tumours that develop blood supply from meningeal arteries with tumour capillaries that completely lack blood-brain barriers. They appear hypervascular on perfusion MR and the capillaries are very leaky and permeable and therefore the CBV measurements may be grossly overestimated or under-estimated on T2* imaging. Multiple intracranial metastatic diseases often do not pose a diagnostic dilemma but a solitary metastatic brain tumour can appear similar to glioma on post-contrast T1 images and CBV maps. However, it has been shown that the perfusion MR may be useful in differentiating solitary metastases and primary glioma based on the difference in the peritumour CBV measurements. [51] This can be explained by the fact that the peritumour edema is pure vasogenic edema in metastatic tumours suggesting no tumour beyond the contrast-enhancing margin in metastases. In high-grade tumours however the perilesional edema may represent a combination of vasogenic edema and tumour infiltration around the perivascular spaces. [52] Zhu et al.,[53] calculated K trans and v e maps in patients with meningioma, glioma and acoustic neuroma. K trans in acoustic neuromas was found to be consistently lower than that observed in meningioma and glioma but v e (size of EES) was significantly higher in acoustic neuroma and also high in meningioma compared to glioma. Primary cerebral lymphoma may mimic demyelinating lesions or tumours but show relative decreases in CBV on perfusion MR may be useful in differentiating between the tumour types which are managed and treated differently. [44],[49] Tumefactive demyelinating lesions may sometimes be difficult to differentiate from primary brain tumours as they may develop a mildly elevated rCBV and characteristic intra-lesion venous enhancement but marked hypovascularity is not seen. [38]

Several studies [41],[42],[43],[54] have shown a statistically strong correlation between tumour rCBV and astrocytoma grading, [Figure 5] as well as conventional angiographic tumour vascularity. Low-grade astrocytomas have significantly lower average CBV than an anaplastic astrocytoma or glioblastoma. [41],[42],[54] Astrocytoma grading using rCBV, must be limited to fibrillary astrocytomas because other gliomas, most notably oligodendrogliomas, may have high rCBV regardless of grade. [55]

The relationship between K trans and grade remains less clear [56],[57],[58],[59] [Figure 3]. We have demonstrated strong relationships between both CBV and K trans and histological grade in gliomas and either measurement, or a combination of the two, show good discriminative power in distinguishing between low- and high-grade tumours. [60] [Figure 6]. Histological grade, patient age, use of adjuvant therapy, degree of surgery, and size of tumour have all also shown, to a lesser extent to have some prognostic value. [61],[62],[63],6[4],[65],[66],[67] Mills et al.,[68] have shown that histological grade remains the most statistically significant predictor of prognosis when compared to CBV and K trans with CBV simply a reflection tumour grade and has no additional prognostic value if histological grading is performed. But K trans demonstrates a statistically significant relationship with prognosis, which is independent of tumour grade.


 :: Imaging in Dementia Top


Neurodegenerative processes including Alzheimer's disease (AD), frontotemporal dementia (FTD) and dementia with Lewy bodies (LBD) can each cause severe dementing syndromes. However, in patients with a combination of neurodegenerative and vascular abnormalities the relative significance of the separate pathological processes to the clinical features of the disease remains unclear.

Ischemic-vascular dementia (IVD) is commonly associated with widespread small ischemic or vascular lesions throughout the brain with predominant involvement of the basal ganglia, white matter, and hippocampus. [69] Several groups have shown that severe lacunar state and micro infarction due to arteriolosclerosis and hypertensive microangiopathy are more common in IVD subjects than in normals and have emphasized the importance of small vascular lesions in the development of dementia. [69],[70],[71],[72] Many groups have suggested that simple scoring schemes of white matter lesion load and distribution are useful in the diagnosis of vascular dementia. [73],[74],[75],[76] However, although white matter lesions are more severe in patients with vascular dementia, [73],[74],[75],[76],[77],[78],[79],[80],[81] they are more prevalent in all dementia groups than in normals.

It is widely considered that AD is distinguishable from normal brains and those affected by vascular dementia (VaD) or frontal lobe dementia from images showing bilateral temporoparietal hypoperfusion or hypometabolism (impaired metabolism).

It has also long been known that AD is more severe in the presence of established cerebral infarction [82],[83] and autopsy studies show 70% of patients with definite AD to have evidence of coexistent cerebrovascular disease and 35% to have had a cerebral infarction. [84],[85],[86],[87] Structural imaging with CT and MRI only revealed mild cortical atrophy in AD but numerous small infarcts in VaD. Oxygen extraction fraction [OEF], especially in the parietotemporal cortex, was found to be raised in probable AD but not in VaD, whereas vascular transit time [VTT] and vascular reactivity [VR] were normal in AD but the VaD patient had prolonged VTT and decreased VR, CBF and cerebral metabolic rate of oxygen (CMRO2). [88]

Combining findings from different modalities, such as atrophy of the medial temporal lobe, as measured with CT, with parietotemporal hypoperfusion as measured with SPECT, can apparently improve diagnostic accuracy for AD, as this combination is much less common in other dementias and rare in normal brains. [89]

The term "mixed dementia" is often used to describe patients with neuropsychological deficits in keeping with AD but with clear evidence of coexistent vascular disease fulfilling the National Institute of Neurological Disorders and Stroke and Association Internationale pour la Recherche er l'Enseignement en Neurosciences (NINDS-AIREN) criteria for the diagnosis of vascular dementia . [90] It has been proposed that coexistent cerebrovascular disease and AD may have a synergistic effect and thus patients present earlier and or have more cognitive impairment than would be expected if either disease were to present in isolation. [91],[92],[93],[94],[95] The CATCH hypothesis put forward by de la Torre proposes that in patients in the early stages of AD or in those at high risk of developing the disorder, the presence of an ischemic vascular insult producing a "critically attained threshold of cerebral hypoperfusion" (CATCH) promotes or triggers the clinical onset of AD. [96],[97],[98],[99]

Virchow-Robin spaces are microscopic perivascular spaces, which surround the perforating arteries that enter the brain but, when dilated they may be seen on MR examinations. We recently demonstrated that VRS dilatation is commoner in diseases associated with microvascular angiopathy data on the [Figure 7]. Abnormal VRS dilatation is shown to be associated with vascular dementia and with treatment resistance in late-onset depression (LOD). [100] A recent study demonstrated that SCE measured by continuous Transcranial Doppler (TCD) of the middle cerebral artery and venous to arterial circulation shunt (v-aCS) indicative of patent foramen ovale (PFO) were commoner in both AD and VaD. [101],[102],[103] A study using quantitative [1H]MRS found that patients with a diagnosis of 'probable AD' had 20% less cerebral (glutamate + glutamine) than normal. [104] The Moats team also found a 50% increase in myoinositol in the cognitively-impaired sample, consistent with the 2002 MRS findings by Waldman et al., of a higher myoinositol:creatine ratio in AD patients compared with controls and patients with vascular dementia. [105]


 :: Conclusions Top


Neuroimaging plays a pivotal role in various degenerative and neoplastic diseases, improving diagnostic accuracy, affecting patient care, monitoring dynamic changes within brain during therapy, and establishing them as the arbiter of novel therapy that may one day prove cure of various brain diseases a reality.

 
 :: References Top

1.Schaefer PW, Hunter GJ, He J, Hamberg LM, Sorensen AG, Schwamm LH, et al. Predicting cerebral ischemic infarct volume with diffusion and perfusion MR imaging. Am J Neuroradiol 2002;23:1785-94.  Back to cited text no. 1      
2.Field AS, Wu YC, Alexander AL. Principal diffusion direction in peritumoral fiber tracts: Color map patterns and directional statistics. Ann N Y Acad Sci 2005;1064:193-201.  Back to cited text no. 2      
3.Thulborn K. Clinical Functional MR Imaging. In: SW A, MRI of the brain and spine. 3 rd ed. Philadelphia: Lipincott Williams and Wilkins; 2002.  Back to cited text no. 3      
4.Tissue plasminogen activator for acute ischemic stroke: The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995;333:1581-7.  Back to cited text no. 4      
5.Makris N, Bates JF. MRI - based volumetric analysis of anatomical consequences of stroke. Hum Brain Mapp 2001:S813.  Back to cited text no. 5      
6.Schellinger PD, Fiebach JB, Jansen O, Ringleb PA, Mohr A, Steiner T, et al. Stroke magnetic resonance imaging within 6 hours after onset of hyperacute cerebral ischemia. Ann Neurol 2001;49:460-9.  Back to cited text no. 6      
7.Srinivas A, Goyal M, Al Azri F. State-of-the-art imaging of acute stroke. Radiographics 2006;26:S75-95.  Back to cited text no. 7      
8.Furlan AJ, Eyding D, Albers GW, Al-Rawi Y, Lees KR, Rowley HA, et al. Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): Evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke 2006;37:1227-31.  Back to cited text no. 8      
9.Hacke W, Albers G, Al-Rawi Y, Bogousslavsky J, Davalos, Eliasziw M, et al.The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): A phase II MRI-based 9- hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 2005;36:66-73.  Back to cited text no. 9      
10.Eastwood JD, Alexander MJ, Petrella JR, Provenzale JM. Dynamic CT perfusion imaging with acetazolamide challenge for the preprocedural evaluation of a patient with symptomatic middle cerebral artery occlusive disease. AJNR Am J Neuroradiol 2002;23:285-7.  Back to cited text no. 10      
11.Fujimura M, Mugikura S, Shimizu H, Tominaga T. Diagnostic value of perfusion - weighted MRI for evaluating postoperative alteration of cerebral hemodynamics following STA-MCA anastomosis in patients with moyampya disease. No Shinkei Geka 2006;34:801-9.  Back to cited text no. 11      
12.Lee SK, Kim DI, Jeong EK, Kim SY, Kim SH, In YK, et al. Postoperative evaluation of Moyamoya disease with perfusion-Weighted MR imaging: Initial Experience. AJNR Am J Neuroradiol 2003;24:741-7.  Back to cited text no. 12      
13.Bell GS, Sander JW. The epidemiology of epilepsy: The size of the problem. Seizure 2001;10:306-14.  Back to cited text no. 13      
14.Bernal B, Altman NR. Evidence-based medicine: Neuroimaging of seizures. Neuroimaging Clin N Am 2003;13:211-24.  Back to cited text no. 14      
15.Sander JW. The epidemiology of epilepsy revisited. Curr Opin Neurol 2003;16:165-70.  Back to cited text no. 15      
16.Wright NB. Imaging in epilepsy: A paediatric perspective. Br J Radiol 2001;74:575-89.  Back to cited text no. 16      
17.Vattipally VR, Bronen RA. MR imaging of epilepsy: Strategies for successful interpretation. Neuroimaging Clin N Am 2004;14:349-72.  Back to cited text no. 17      
18.Jack CR Jr. Hippocampal T2 relaxometry in epilepsy: Past, present, and future. AJNR Am J Neuroradiol 1996;17:1811-4.  Back to cited text no. 18      
19.Bronen RA, Knowlton R, Garwood M, Maravilla KR, Jack CR Jr. High resolution imaging in epilepsy. Epilepsia 2002;43:11-8.  Back to cited text no. 19      
20.Grant PE, Barkovich AJ, Wald LL, Dillon WP, Laxer KD, Vigneron DB. High-resolution surface-coil MR of cortical lesions in medically refractory epilepsy: A prospective study. AJNR Am J Neuroradiol 1997; 8:291-301.  Back to cited text no. 20      
21.Arora V, Nijjar IB, Mahajan DS, Sandhu PS, Singh JP, Chopra R. MRI in seizure disorder - a pictorial essay. Ind J Radiol Imag 2005;15:331-40.  Back to cited text no. 21      
22.Cascino GD, Jack CR Jr, Parisi JE, Sharbrough FW, Hirschorn KA, Meyer FB, et al. Magnetic resonance imaging-based volume studies in temporal lobe epilepsy: Pathological correlations. Ann Neurol 1991;30:31-6.  Back to cited text no. 22      
23.Jack CR Jr, Sharbrough FW, Twomey CK, Cascino GD, Hirschorn KA, Marsh WR, et al. Temporal lobe seizures: Lateralization with MR volume measurements of the hippocampal formation. Radiology 1990;175:423-9.  Back to cited text no. 23      
24.Jackson GD, Connelly A, Duncan JS, Grόnewald RA, Gadian DG. Detection of hippocampal pathology in intractable partial epilepsy: Increased sensitivity using quantitative T2 relaxometry. Neurology 1993;43:1793-9.  Back to cited text no. 24      
25.Jackson GD, Kim SE, Fitt GJ, Mitchell AL, Syngeniotis A, Berkovic SF. Hippocampal T(2) abnormalities correlate with antecedent events and help to predict seizure intractability. Dev Neurosci 1999;21:200-6.  Back to cited text no. 25      
26.Kuzniecky R. Magnetic resonance spectroscopy in focal epilepsy: 31P and 1H spectroscopy. Rev Neurol (Paris) 1999;155:495-8.  Back to cited text no. 26      
27.Woermann FG, Mclean MA, Bartlett PA, Parker GJ, Barker GJ, Duncan JS. Short echo time single-voxel 1H magnetic resonance spectroscopy in magnetic resonance imaging-negative temporal lobe epilepsy: Different biochemical profile compared with hippocampal sclerosis. Ann Neurol 1999;45:369-76.  Back to cited text no. 27      
28.Petroff OA, Prichard JW, Behar KL, Alger JR, Shulman RG. In vivo phosphorus nuclear magnetic resonance spectroscopy in status epilepticus. Ann Neurol 1984;16:169-77.  Back to cited text no. 28      
29.Fong GC, Fong JK. Recent advances in the diagnosis and management of epilepsy. Hong Kong Med J 2001;7:73-84.  Back to cited text no. 29      
30.Theodore W. Imaging in epilepsy. Curr Sci 2000;82:689-97.  Back to cited text no. 30      
31.Chugani HT, Shields WD, Shewmon DA, Olson DM, Phelps ME, Peacock WJ. Infantile spasms: I. PET identifies focal cortical dysgenesis in cryptogenic cases for surgical treatment. Ann Neurol 1990;27:406-13.  Back to cited text no. 31      
32.Won HJ, Chang KH, Cheon JE, Kim HD, Lee DS Han MH, et al. Comparison of MR imaging with PET and ictal SPECT in 118 patients with intractable epilepsy. AJNR Am J Neuroradiol 1999;20:593-9.  Back to cited text no. 32      
33.Wieshmann UC, Clark CA, Symms MR, Barker GJ, Birnie KD, Shorvon SD. Water diffusion in the human hippocampus in epilepsy. Magn Reson Imaging 1999;17:29-36.  Back to cited text no. 33      
34.Rugg-Gunn FJ, Symms MR. Novel MR contrasts to reveal more about the brain. Neuroimaging Clin N Am 2004;14:449-70.  Back to cited text no. 34      
35.Siegel AM, Jobst BC, Thadani VM, Rhodes CH, Lewis PJ, Roberts DW, et al. Medically intractable, localisation-related epilepsy with normal MRI: Presurgical evaluation and surgical outcome in 43 patients. Epilepsia 2001;42:883-8.  Back to cited text no. 35      
36.Kleihues P, Burger PC, Scheithauer BW. The new WHO classification of brain tumours. Brain Pathol 1993;3:255-68.  Back to cited text no. 36      
37.Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 2002;61:215-25.  Back to cited text no. 37      
38.Cha S, Pierce S, Knopp EA, Johnson G, Yang C, Ton A, et al. Dynamic contrast-enhanced T2*-weighted MR imaging of tumefactive demyelinating lesions. AJNR Am J Neuroradiol 2001;22:1109-16.  Back to cited text no. 38      
39.Kepes JJ. Large focal tumor-like demyelinating lesions of the brain: Intermediate entity between multiple sclerosis and acute disseminated encephalomyelitis? A study of 31 patients. Ann Neurol 1993;33:18-27.  Back to cited text no. 39      
40.De Stefano N, Caramanos Z, Preul MC, Francis G, Antel JP, Arnold DL. In vivo differentiation of astrocytic brain tumors and isolated demyelinating lesions of the type seen in multiple sclerosis using 1H magnetic resonance spectroscopic imaging. Ann Neurol 1998;44:273-8.  Back to cited text no. 40      
41.Aronen HJ, Gazit IE, Louis DN, Buchbinder BR, Pardo FS, Weisskoff RM, et al. Cerebral blood volume maps of gliomas: Comparison with tumor grade and histologic findings. Radiology 1994;191:41-51.  Back to cited text no. 41      
42.Knopp EA, Cha S, Johnson G, Mazumdar A, Golfinos JG, Zagzag D, et al. Glial neoplasms: Dynamic contrast-enhanced T2*-weighted MR imaging. Radiology 1999;211:791-8.  Back to cited text no. 42      
43.Sugahara T, Korogi Y, Kochi M, Ikushima I, Hirai T, Okuda T, et al. Correlation of MR imaging-determined cerebral blood volume maps with histologic and angiographic determination of vascularity of gliomas. AJNR Am J Roentgenol 1998;171:1479-86.  Back to cited text no. 43      
44.Sugahara T, Korogi Y, Shigematsu Y, Hirai T, Ikushima I, Liang L, et al. Perfusion-sensitive MRI of cerebral lymphomas: A preliminary report. J Comput Assist Tomogr 1999;23:232-7.  Back to cited text no. 44      
45.Alavi JB, Alavi A, Chawluk J, Kushner M, Powe J, Hickey W, et al. Positron emission tomography in patients with glioma: A predictor of prognosis. Cancer 1988;62:1074-8.  Back to cited text no. 45      
46.Boxerman JL, Hamberg LM, Rosen BR, Weisskoff RM. MR contrast due to intravascular magnetic susceptibility perturbations. Magn Reson Med 1995;34:555-66.  Back to cited text no. 46      
47.Maeda M, Itoh S, Kimura H, Iwasaki T, Hayashi N, Yamamoto K, et al. Tumor vascularity in the brain: Evaluation with dynamic susceptibility-contrast MR imaging. Radiology 1993;189:233-8.  Back to cited text no. 47      
48.Rosen BR, Belliveau JW, Buchbinder BR, McKinstry RC, Porkka LM, Kennedy DN, et al. Contrast agents and cerebral hemodynamics. Magn Reson Med 1991;19:285-92.  Back to cited text no. 48      
49.Cha S. Perfusion MR imaging of brain tumors. Top Magn Reson Imaging 2004;15:279-89.  Back to cited text no. 49      
50.Rosen BR, Aronen HJ, Kwong KK, Belliveau JW, Hamberg LM, Fordham JA. Advances in clinical neuroimaging: Functional MR imaging techniques. Radiographics 1993;13:889-96.  Back to cited text no. 50      
51.Law M, Cha S, Knopp EA, Johnson G, Arnett J, Litt AW. High-grade gliomas and solitary metastases: Differentiation by using perfusion and proton spectroscopic MR imaging. Radiology 2002;222:715-21.  Back to cited text no. 51      
52.Bertossi M, Virgintino D, Maiorano E, Occhiogrosso M, Roncali L. Ultrastructural and morphometric investigation of human brain capillaries in normal and peritumoral tissues. Ultrastruct Pathol 1997;21:41-9.  Back to cited text no. 52      
53.Zhu XP, Li KL, Kamaly-Asl ID, Checkley DR, Tessier JJ, Waterton JC, et al. Quantification of endothelial permeability, leakage space, and blood volume in brain tumors using combined T 1 and T 2 * contrast-enhanced dynamic MR imaging. J Magn Reson Imaging 2000;11:575-85.  Back to cited text no. 53      
54.Lev MH, Ozsunar Y, Henson JW, Rasheed AA, Barest GD, Harsh GR 4th, et al. Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: Confounding effect of elevated rCBV of oligodendrogliomas [corrected]. AJNR Am J Neuroradiol 2004;25:214-21.  Back to cited text no. 54      
55.Cha S, Tihan T, Crawford F, Fischbein NJ, Chang S, Bollen A, et al. Differentiation of low-grade oligodendrogliomas from low-grade astrocytomas by using quantitative blood-volume measurements derived from dynamic susceptibility contrast-enhanced MR imaging. ANJR Am J Neuroradiol 2005;26:266-73.  Back to cited text no. 55      
56.Law M, Yang S, Babb JS, Knopp EA, Golfinos JG, Zagzag D, et al. Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade. AJNR Am J Neuroradiol 2004;25:746-55.  Back to cited text no. 56      
57.Ludemann L, Grieger W, Wurm R, Budzisch M, Hamm B, Zimmer C. Comparison of dynamic contrast-enhanced MRI with WHO tumor grading for gliomas. Eur Radiol 2001;11:1231-41.  Back to cited text no. 57      
58.Provenzale JM, Wang GR, Brenner T, Petrella JR, Sorensen AG. Comparison of permeability in high-grade and low-grade brain tumors using dynamic susceptibility contrast MR imaging. AJR Am J Roentgenol 2002;178:711-6.  Back to cited text no. 58      
59.Roberts HC, Roberts TP, Brasch RC, Dillon WP. Quantitative measurement of microvascular permeability in human brain tumors achieved using dynamic contrast-enhanced MR imaging: Correlation with histologic grade. AJNR Am J Neuroradiol 2000;21:891-9.  Back to cited text no. 59      
60.Patankar TA, Haroon HA, Mills SJ, Baleriaux D, Buckley DL, Parker GJ, et al. Is Volume transfer coefficient (K trans ) related to histological grade in human gliomas? AJNR Am J Neuroradiol 2005;26:2455-65.  Back to cited text no. 60      
61.Bauman G, Lote K, Larson D, Stalpers L, Leighton C, Fisher B, et al. Pretreatment factors predict overall survival for patients with low-grade glioma: A recursive partitioning analysis. Int J Radiat Oncol Biol Phys 1999;45:923-9.  Back to cited text no. 61      
62.Pignatti F, van den Bent M, Curran D, Debruyne C, Sylvester R, Therasse P, et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 2002;20:2076-84.  Back to cited text no. 62      
63.Scott CB, Scarantino C, Urtasun R, Movsas B, Jones CU, Simpson JR, et al. Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: A report using RTOG 90-06. Int J Radiat Oncol Biol Phys 1998;40:51-5.  Back to cited text no. 63      
64.Fazeny-Dφrner B, Wenzel C, Veitl M, Piribauer M, Rφssler K, Dieckmann K, et al. Survival and prognostic factors of patients with unresectable glioblastoma multiforme. Anticancer Drugs 2003;14:305-12.  Back to cited text no. 64      
65.Kreth FW, Berlis A, Spiropoulou V, Faist M, Scheremet R, Rossner R, et al. The role of tumor resection in the treatment of glioblastoma multiforme in adults. Cancer 1999;86:2117-23.  Back to cited text no. 65      
66.Paszat L, Laperriere N, Groome P, Schulze K, Mackillop W, Holowaty E. A population-based study of glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2001;51:100-7.  Back to cited text no. 66      
67.Stewart LA. Chemotherapy in adult high-grade glioma: A systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002;359:1011-8.  Back to cited text no. 67      
68.Mills SJ, Patankar TA, Haroon HA, Baleriaux D, Swindell R, Jackson A. Do cerebral blood volume and contrast transfer coefficient predict prognosis in human glioma? AJNR Am J Neuroradiol 2006;27:853-8.  Back to cited text no. 68      
69.Jellinger KA. The pathology of ischemic-vascular dementia: An update. J Neurol Sci 2002;204:153-7.  Back to cited text no. 69      
70.Erkinjuntti T, Benavente O, Eliasziw M, Munoz DG, Sulkava R, Haltia M, et al. Diffuse vacuolization (spongiosis) and arteriolosclerosis in the frontal white matter occurs in vascular dementia. Arch Neurol 1996;53:325-32.  Back to cited text no. 70      
71.Esiri MM Wilcock GK, Morris JH. Neuropathological assessment of the lesions of significance in vascular dementia. J Neurol Neurosurg Psychiatry 1997;63:749-53.  Back to cited text no. 71      
72.Hulette C, Nochlin D, McKeel D, Morris JC, Mirra SS, Sumi SM, et al. Clinical-neuropathologic findings in multi-infarct dementia: A report of six autopsied cases. Neurology 1997;48:668-72.  Back to cited text no. 72      
73.Erkinjuntti T. Diagnosis and management of vascular cognitive impairment and dementia. J Neural Transm Suppl 2002:91-109.  Back to cited text no. 73      
74.Hentschel F, Kreis M, Damian M, Krumm B. Microangiopathic lesions of white matter: Quantitation of cerebral MRI findings and correlation with psychological tests. Nervenarzt 2003;74:355-61.  Back to cited text no. 74      
75.Wahlund LO, Basun H, Almkvist O, Andersson-Lundman G, Julin P, Saaf J. White matter hyperintensities in dementia: Does it matter? Magn Reson Imaging 1994;12:387-94.  Back to cited text no. 75      
76.Leys D, Pasquier F, Lucas C, Pruvo JP. Magnetic resonance imaging in vascular dementia. J Mal Vasc 1995;20:194-202.  Back to cited text no. 76      
77.Barber R, Scheltens P, Gholkar A, Ballard C, McKeith I, Ince P, et al.White matter lesions on magnetic resonance imaging in dementia with Lewy bodies, Alzheimer's disease, vascular dementia, and normal aging. J Neurol Neurosurg Psychiatry 1999;67:66-72.  Back to cited text no. 77      
78.Chui H. Dementia due to subcortical ischemic vascular disease. Clin Cornerstone 2001;3:40-51.  Back to cited text no. 78      
79.Pasquier F, Henon H, Leys D. Relevance of white matter changes to pre- and poststroke dementia. Ann N Y Acad Sci 2000;903:466-9.  Back to cited text no. 79      
80.Udaka F, Sawada H, Kameyama M. White matter lesions and dementia: MRI-pathological correlation. Ann N Y Acad Sci 2002;977:411-5.  Back to cited text no. 80      
81.Varma AR, Laitt R, Lloyd JJ, Carson KJ, Snowden JS, Neary D, et al. Diagnostic value of high signal abnormalities on T2 weighted MRI in the differentiation of Alzheimer's, frontotemporal and vascular dementias. Acta Neurol Scand 2002;105:355-64.  Back to cited text no. 81      
82.Heyman A, Fillenbaum GG, Welsh-Bohmer KA, Gearing M, Mirra SS, Mohs RC, et al. Cerebral infarcts in patients with autopsy-proven Alzheimer's disease: CERAD, part XVIII: Consortium to Establish a Registry for Alzheimer's Disease. Neurology 1998;51:159-62.  Back to cited text no. 82      
83.Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR, et al. Brain infarction and the clinical expression of Alzheimer disease: The Nun Study. JAMA 1997;277:813-7.  Back to cited text no. 83      
84.Kalaria R. Similarities between Alzheimer's disease and vascular dementia. J Neurol Sci 2002;203-204:29-34.  Back to cited text no. 84      
85.Kalaria RN. The blood-brain barrier and cerebrovascular pathology in Alzheimer's disease. Ann N Y Acad Sci 1999;893:113-25.  Back to cited text no. 85      
86.Kalaria RN. Small vessel disease and Alzheimer's dementia: Pathological considerations. Cerebrovasc Dis 2002;13:48-52.  Back to cited text no. 86      
87.Kalaria RN. Vascular factors in Alzheimer's disease. Int Psychogeriatr 2003;15:47-52.  Back to cited text no. 87      
88.Nagata K, Kondoh Y, Atchison R, Sato M, Satoh Y, Watahiki Y, et al. Vascular and metabolic reserve in Alzheimer's disease. 2000;21:301-7.  Back to cited text no. 88      
89.Jobst KA, Barnetson LP, Shepstone BJ. Accurate prediction of histologically confirmed Alzheimer's disease and the differential diagnosis of dementia: The use of NINCDS-ADRDA and DSM-111-R criteria, SPECT, X-ray, CT, and Apo E4 in medial temporal lobe dementias: Oxford Project to Investigate Memory and Aging. Int Psychogeriatr 1998;10:271-302.  Back to cited text no. 89      
90.Romαn GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, et al. Vascular dementia: Diagnostic criteria for research studies: Report of the NINDS-AIREN International Workshop. Neurology 1993;43:250-60.  Back to cited text no. 90      
91.Zekry D, Duyckaerts C, Belmin J, Geoffre C, Moulias R, Hauw JJ. Alzheimer's disease and brain infarcts in the elderly: Agreement with neuropathology. J Neurol 2002;249:1529-34.  Back to cited text no. 91      
92.Zekry D, Duyckaerts C, Moulias R, Belmin J, Geoffre C, Herrmann F, et al. Degenerative and vascular lesions of the brain have synergistic effects in dementia of the elderly. Acta Neuropathol 2002;103:481-7.  Back to cited text no. 92      
93.Buee L, Hof PR, Delacourte A. Brain microvascular changes in Alzheimer's disease and other dementias. Ann N Y Acad Sci 1997;826:7-24.  Back to cited text no. 93      
94.Kalaria RN. The role of cerebral ischemia in Alzheimer's disease. Neurobiol Aging 2000;21:321-30.  Back to cited text no. 94      
95.Kudo T, Imaizumi K, Tanimukai H, Katayama T, Sato N, Nakamura Y, et al. Are cerebrovascular factors involved in Alzheimer's disease? Neurobiol Aging 2000;21:215-24.  Back to cited text no. 95      
96.de la Torre JC. Alzheimer disease as a vascular disorder: Nosological evidence. Stroke 2002;33:1152-62.  Back to cited text no. 96      
97.de la Torre JC. Vascular basis of Alzheimer's pathogenesis. Ann N Y Acad Sci 2002;977:196-215.  Back to cited text no. 97      
98.de la Torre JC. Critically attained threshold of cerebral hypoperfusion: Can it cause Alzheimer's disease? Ann N Y Acad Sci 2000;903:424-36.  Back to cited text no. 98      
99.de la Torre JC. Critically attained threshold of cerebral hypoperfusion: The CATCH hypothesis of Alzheimer's pathogenesis. Neurobiol Aging 2000;21:331-42.  Back to cited text no. 99      
100.Patankar TF, Mitra D, Varma A, Snowden J, Neary D, Jackson A. Dilatation of the Virchow-Robin space is a sensitive indicator of cerebral microvascular disease: Study in elderly patients with dementia. Am J Neuroradiol 2005;26:1512-20.  Back to cited text no. 100      
101.Purandare N, Burns A, Daly KJ, Hardicre J, Morris J, Macfarlane G, et al. Cerebral emboli as a potential cause of Alzheimer's disease and vascular dementia: Case-control study. BMJ 2006;332:1119-24.  Back to cited text no. 101      
102.Purandare N, Welsh S, Hutchinson S, Riding G, Burns A, McCollum C. Cerebral emboli and paradoxical embolisation in dementia: A pilot study. Int J Geriatr Psychiatry 2005;20:12-6.  Back to cited text no. 102      
103.Purandare N, Oude Voshaar RC, Burns A, Velupandian UM, McCollum C. Paradoxical embolization: A potential cause of cerebral damage in Alzheimer's disease? Neurol Res 2006;28:679-84.  Back to cited text no. 103      
104.Moats RA, Ernst T, Shonk TK, Ross BD. Abnormal cerebral metabolite concentrations in patients with probable Alzheimer disease. Magn Reson Med 1994;32:110-5.  Back to cited text no. 104      
105.Waldman AD, Rai GS, McConnell JR, Chaudry M, Grant D. Clinical brain proton magnetic resonance spectroscopy for management of Alzheimer's and sub-cortical ischemic vascular dementia in older people. Arch Gerontol Geriatr 2002;35:137-42.  Back to cited text no. 105      


    Figures

  [Figure 1], [Figure 2], [Figure 3], [Figure 4], [Figure 5], [Figure 6], [Figure 7]



 

Top
Print this article  Email this article
Previous article Next article
Online since 12th February '04
2004 - Journal of Postgraduate Medicine
Official Publication of the Staff Society of the Seth GS Medical College and KEM Hospital, Mumbai, India
Published by Wolters Kluwer - Medknow